Efficacy is only part of the equation.
In this clip, the panel explains how toxicity profiles, infusion schedules, growth factor use, and patient logistics shape real-world treatment decisions between Datopotamab-deruxtecan and Sacituzumab govitecan.
A powerful reminder that shared decision-making goes beyond trial endpoints.
Which ADC to choose for 1st line mTNBC? Toxicity & Logistics Matter
You may also like
Recommended Videos
